John Andrew Samuel Purchases 2,000,000 Shares of Tissue Regenix Group PLC (TRX) Stock
Tissue Regenix Group PLC (LON:TRX) insider John Andrew Samuel bought 2,000,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was acquired at an average price of GBX 10 ($0.13) per share, for a total transaction of £200,000 ($260,450.58).
Tissue Regenix Group PLC (LON TRX) remained flat at GBX 11.50 during mid-day trading on Wednesday. The company had a trading volume of 42,714 shares. The company’s 50-day moving average price is GBX 12.16 and its 200 day moving average price is GBX 15.51. The stock’s market capitalization is GBX 85.47 million. Tissue Regenix Group PLC has a one year low of GBX 10.65 and a one year high of GBX 21.00.
COPYRIGHT VIOLATION WARNING: “John Andrew Samuel Purchases 2,000,000 Shares of Tissue Regenix Group PLC (TRX) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/09/john-andrew-samuel-purchases-2000000-shares-of-tissue-regenix-group-plc-trx-stock.html.
TRX has been the topic of a number of research reports. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 39 ($0.51) target price on shares of Tissue Regenix Group PLC in a report on Friday, July 21st. Beaufort Securities reiterated a “speculative buy” rating on shares of Tissue Regenix Group PLC in a report on Monday, June 5th.
Tissue Regenix Group PLC Company Profile
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.
Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.